المؤلفون: le Coutre, P D, Giles, F J, Hochhaus, A, Apperley, J F, Ossenkoppele, G J, Blakesley, R, Shou, Y, Gallagher, N J, Baccarani, M, Cortes, J, Kantarjian, H M

مصطلحات موضوعية: nilotinib, chronic myeloid leukemia (cml), bcr-abl, imatinib, chronic myelogenous leukemia, harmonizing current methodology, tyrosine kinase inhibitors, bcr-abl transcripts, in-vitro activity, cytogenetic responses, selective inhibitor, domain mutations, formerly amn107, working party

العلاقة: Leukemia; le Coutre, P D; Giles, F J; Hochhaus, A; Apperley, J F; Ossenkoppele, G J; Blakesley, R; Shou, Y; Gallagher, N J; Baccarani, M; Cortes, J; Kantarjian, H M (2011). Nilotinib in patients with ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. Leukemia 26 (6), 1189-1194; 0887-6924,1476-5551; http://hdl.handle.net/10379/12402Test

الإتاحة: https://doi.org/10.1038/leu.2011.323Test
http://hdl.handle.net/10379/12402Test

المؤلفون: Giles, F J, Kantarjian, H M, le Coutre, P D, Baccarani, M, Mahon, F-X, Blakesley, R E, Gallagher, N J, Gillis, K, Goldberg, S L, Larson, R A, Hochhaus, A, Ottmann, O G

مصطلحات موضوعية: nilotinib, chronic myeloid leukemia, blastic phase, bcr-abl, imatinib resistance, mutations, chronic myelogenous leukemia, tyrosine kinase inhibitors, formerly amn107, dasatinib, cml, therapy, crisis, transformation, failure, cells

العلاقة: Leukemia; Giles, F J; Kantarjian, H M; le Coutre, P D; Baccarani, M; Mahon, F-X; Blakesley, R E; Gallagher, N J; Gillis, K; Goldberg, S L; Larson, R A; Hochhaus, A; Ottmann, O G (2011). Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia 26 (5), 959-962; 0887-6924,1476-5551; http://hdl.handle.net/10379/11636Test

الإتاحة: https://doi.org/10.1038/leu.2011.355Test
http://hdl.handle.net/10379/11636Test

المؤلفون: Cortes, J. E., Hochhaus, A., le Coutre, P. D., Rosti, G., Pinilla-Ibarz, J., Jabbour, E., Gillis, K., Woodman, R. C., Blakesley, R. E., Giles, F. J., Kantarjian, H. M., Baccarani, M.

مصطلحات موضوعية: abl tyrosine kinase, chronic myelogenous leukemia, bcr-abl, inhibitor nilotinib, formerly amn107, pdgf receptors, resistance, growth

العلاقة: Blood; Cortes, J. E. Hochhaus, A.; le Coutre, P. D.; Rosti, G.; Pinilla-Ibarz, J.; Jabbour, E.; Gillis, K.; Woodman, R. C.; Blakesley, R. E.; Giles, F. J.; Kantarjian, H. M.; Baccarani, M. (2011). Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib. Blood 117 (21), 5600-5606; 0006-4971,1528-0020; http://hdl.handle.net/10379/10921Test

الإتاحة: https://doi.org/10.1182/blood-2010-11-318949Test
http://hdl.handle.net/10379/10921Test

المؤلفون: Andreas Hochhaus, J. F. Apperley, Gert J. Ossenkoppele, Francis J. Giles, Neil Gallagher, P. le Coutre, Yaping Shou, Michele Baccarani, Hagop M. Kantarjian, Jorge E. Cortes, Rick E. Blakesley

المساهمون: Hematology, CCA - Innovative therapy

المصدر: Leukemia, 26(6), 1189-1194. Nature Publishing Group
le Coutre, P, Giles, F, Hochhaus, A, Apperley, J, Ossenkoppele, G J, Blakesley, R, Shou, Y, Gallagher, N, Baccarani, M, Cortes, J & Kantarjian, H 2012, ' Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results ', Leukemia, vol. 26, no. 6, pp. 1189-1194 . https://doi.org/10.1038/leu.2011.323Test

مصطلحات موضوعية: Oncology, Male, Cancer Research, bcr-abl, Fusion Proteins, bcr-abl, bcr-abl transcripts, chronic myeloid leukemia (cml), Piperazines, formerly amn107, hemic and lymphatic diseases, tyrosine kinase inhibitors, Aged, 80 and over, Myeloid leukemia, Hematology, Middle Aged, Protein-Tyrosine Kinases, chronic myelogenous leukemia, Treatment Outcome, harmonizing current methodology, Benzamides, Leukemia, Myeloid, Chronic-Phase, Imatinib Mesylate, Female, Month follow up, medicine.drug, Adult, medicine.medical_specialty, domain mutations, Leukemia, Myeloid, Accelerated Phase, in-vitro activity, working party, Young Adult, Internal medicine, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, medicine, Humans, In patient, Protein Kinase Inhibitors, nilotinib, Accelerated phase, Aged, Imatinib resistance, business.industry, cytogenetic responses, Imatinib, Pyrimidines, imatinib, selective inhibitor, Nilotinib, Drug Resistance, Neoplasm, Immunology, business, Follow-Up Studies

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5d7cbdb9d38f85c85a0818a29fe8675Test
https://hdl.handle.net/1871/42787Test

المؤلفون: Javier Pinilla-Ibarz, Rick E. Blakesley, Francis J. Giles, Andreas Hochhaus, Gianantonio Rosti, Hagop M. Kantarjian, Elias Jabbour, Jorge E. Cortes, Kathryn Gillis, Richard C. Woodman, Michele Baccarani, Philipp le Coutre

المصدر: Blood. 117:5600-5606

مصطلحات موضوعية: Male, Myeloid, Clinical Trials and Observations, bcr-abl, Biochemistry, Gastroenterology, Piperazines, formerly amn107, hemic and lymphatic diseases, Medicine, Aged, 80 and over, Myeloid leukemia, Hematology, Middle Aged, Protein-Tyrosine Kinases, Survival Rate, chronic myelogenous leukemia, Leukemia, Treatment Outcome, medicine.anatomical_structure, Tolerability, Benzamides, Leukemia, Myeloid, Chronic-Phase, Imatinib Mesylate, Female, inhibitor nilotinib, medicine.drug, Adult, medicine.medical_specialty, growth, Immunology, Leukemia, Myeloid, Accelerated Phase, resistance, pdgf receptors, Internal medicine, Humans, neoplasms, Aged, business.industry, Imatinib, Cell Biology, medicine.disease, Pyrimidines, Imatinib mesylate, Nilotinib, Drug Resistance, Neoplasm, abl tyrosine kinase, business, Chronic myelogenous leukemia

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19047525af95cf3304303b35d1303110Test
https://doi.org/10.1182/blood-2010-11-318949Test

المؤلفون: Montemurro, M, Schöffski, Patrick, Reichardt, P, Gelderblom, H, Schuette, J, Hartmann, J. T, von Moos, R, Seddon, B, Joensuu, H, Wendtner, C. M, Weber, E, Gruenwald, V, Roth, A, Leyvraz, S

مصطلحات موضوعية: gastrointestinal stromal tumour, gist, nilotinib, sunitinib, imatinib, tyrosine kinase inhibitor, compassionate use, chronic myelogenous leukemia, population-based incidence, endothelial growth-factor, bcr-abl, formerly amn107, dose imatinib, kit, mesylate, survival

العلاقة: European journal of cancer vol:45 issue:13 pages:2293-2297; https://lirias.kuleuven.be/handle/123456789/257499Test; http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=DOISource&SrcApp=PRODUCT_NAME&KeyAID=10.1016%2Fj.ejca.2009.04.030&DestApp=DOI&SrcAppSID=APP_SID&SrcJTitle=WURS_TITLETest

الإتاحة: https://lirias.kuleuven.be/handle/123456789/257499Test

المؤلفون: P. le Coutre, Neil Gallagher, Richard A. Larson, Andreas Hochhaus, Francis J. Giles, Francois-Xavier Mahon, Hagop M. Kantarjian, Michele Baccarani, K. Gillis, Oliver G. Ottmann, Rick E. Blakesley, Stuart L. Goldberg

المصدر: Leukemia. 26(5)

مصطلحات موضوعية: Cancer Research, Myeloid, bcr-abl, Gastroenterology, Piperazines, formerly amn107, hemic and lymphatic diseases, tyrosine kinase inhibitors, dasatinib, Myeloid leukemia, Hematology, Middle Aged, Protein-Tyrosine Kinases, failure, Leukemia, chronic myelogenous leukemia, medicine.anatomical_structure, crisis, Oncology, Benzamides, Imatinib Mesylate, cml, medicine.drug, Adult, medicine.medical_specialty, Adolescent, Antineoplastic Agents, Neutropenia, Blastic Phase, Young Adult, chronic myeloid leukemia, Internal medicine, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, medicine, Humans, nilotinib, blastic phase, Aged, therapy, business.industry, transformation, medicine.disease, mutations, Survival Analysis, Transplantation, Imatinib mesylate, Pyrimidines, Nilotinib, Drug Resistance, Neoplasm, Immunology, imatinib resistance, cells, business, Blast Crisis

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b74829645db2df589de0884043ca68f8Test
https://pubmed.ncbi.nlm.nih.gov/22157807Test